Your AI-Trained Oncology Knowledge Connection!

Andrew G. Gianoukakis, MD

home / authors / andrew-g.-gianoukakis,-md

Articles

Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid Cancer

February 4th 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.

$Progress in Treating RAI-Refractory DTC$

Progress in Treating RAI-Refractory DTC

Andrew G. Gianoukakis, MD

September 25th 2020

$Real-World Insight: Lenvatinib for RAI-Refractory DTC$

Real-World Insight: Lenvatinib for RAI-Refractory DTC

Andrew G. Gianoukakis, MD

September 25th 2020

$Lenvatinib Data for RAI-Refractory DTC$

Lenvatinib Data for RAI-Refractory DTC

Andrew G. Gianoukakis, MD

September 25th 2020

$Systemic Therapy for RAI-Refractory DTC$

Systemic Therapy for RAI-Refractory DTC

Andrew G. Gianoukakis, MD

September 25th 2020

Recommendations for Treating Patients With DTC

Andrew G. Gianoukakis, MD

September 25th 2020

Case Impressions: A 73-Year-Old Woman With DTC

Andrew G. Gianoukakis, MD

September 25th 2020

A 73-Year-Old Woman With Differentiated Thyroid Cancer

Andrew G. Gianoukakis, MD

September 25th 2020

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.